Kazia Therapeutics (KZIA) announced that it has entered into a definitive agreement for the purchase and sale of up to an aggregate of 1,333,333 of the company’s American Depositary Shares, each ...
Kazia Therapeutics (KZIA) provided a regulatory update on paxalisib for the treatment of glioblastoma, GBM, following its Type C clinical meeting with the United States Food and Drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback